Adarx Pharmaceuticals Inc., a late-stage developer of gene therapies, raised $446.3 million in an upsized initial public offering that priced at the top of its marketed range.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.